Cipher Pharmaceuticals Inc. (TSX: CPH)
Canada
· Delayed Price · Currency is CAD 14.72
+0.07 (0.48%)
Nov 20, 2024, 4:00 PM EST
Cipher Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 26.46 | 21.16 | 20.68 | 21.94 | 21.61 | 22.45 | Upgrade
|
| Revenue Growth (YoY) | 25.11% | 2.36% | -5.78% | 1.56% | -3.76% | -1.31% | Upgrade
|
| Cost of Revenue | 5.09 | 4.07 | 3.99 | 3.68 | 3.06 | 2.91 | Upgrade
|
| Gross Profit | 21.38 | 17.09 | 16.68 | 18.26 | 18.55 | 19.55 | Upgrade
|
| Selling, General & Admin | 8.68 | 5.43 | 4.55 | 5.11 | 6.26 | 7.65 | Upgrade
|
| Research & Development | 0.03 | 0.14 | 0.1 | 0.09 | 0.13 | 0.4 | Upgrade
|
| Operating Expenses | 11.49 | 6.79 | 5.63 | 5.2 | 6.39 | 8.04 | Upgrade
|
| Operating Income | 9.88 | 10.3 | 11.05 | 13.06 | 12.16 | 11.5 | Upgrade
|
| Interest Expense | - | - | - | -0.08 | -0.32 | -0.97 | Upgrade
|
| Interest & Investment Income | 1.43 | 1.87 | 0.46 | - | 0.03 | 0.18 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.04 | 0.78 | -0.04 | 0.08 | 0.09 | -0.11 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | 0.01 | 0 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | 11.35 | 12.95 | 11.48 | 13.07 | 11.97 | 10.62 | Upgrade
|
| Merger & Restructuring Charges | -1.86 | -0.27 | - | - | -0.15 | -1.45 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.76 | - | - | Upgrade
|
| Asset Writedown | - | - | - | - | -5.28 | -3.45 | Upgrade
|
| Legal Settlements | - | - | - | -1.25 | - | - | Upgrade
|
| Pretax Income | 9.49 | 12.68 | 11.48 | 11.06 | 6.54 | 5.71 | Upgrade
|
| Income Tax Expense | -6.37 | -7.7 | -15.16 | 3.3 | 2.15 | 3.07 | Upgrade
|
| Earnings From Continuing Operations | 15.86 | 20.38 | 26.64 | 7.76 | 4.39 | 2.64 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | 0.16 | 0.6 | Upgrade
|
| Net Income | 15.86 | 20.38 | 26.64 | 7.76 | 4.55 | 3.24 | Upgrade
|
| Net Income to Common | 15.86 | 20.38 | 26.64 | 7.76 | 4.55 | 3.24 | Upgrade
|
| Net Income Growth | -51.08% | -23.48% | 243.34% | 70.54% | 40.31% | 497.05% | Upgrade
|
| Shares Outstanding (Basic) | 24 | 25 | 25 | 27 | 27 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 25 | 25 | 26 | 27 | 27 | 27 | Upgrade
|
| Shares Change (YoY) | -2.82% | -1.46% | -3.84% | -1.96% | 1.52% | -0.15% | Upgrade
|
| EPS (Basic) | 0.65 | 0.82 | 1.05 | 0.29 | 0.17 | 0.12 | Upgrade
|
| EPS (Diluted) | 0.63 | 0.80 | 1.03 | 0.29 | 0.17 | 0.12 | Upgrade
|
| EPS Growth | -50.00% | -22.33% | 255.17% | 74.74% | 37.44% | 672.66% | Upgrade
|
| Free Cash Flow | -66.98 | 15.98 | 10.64 | 13.81 | 11.68 | 7.14 | Upgrade
|
| Free Cash Flow Per Share | -2.69 | 0.63 | 0.41 | 0.51 | 0.43 | 0.26 | Upgrade
|
| Gross Margin | 80.78% | 80.77% | 80.69% | 83.21% | 85.85% | 87.06% | Upgrade
|
| Operating Margin | 37.35% | 48.68% | 53.45% | 59.51% | 56.30% | 51.23% | Upgrade
|
| Profit Margin | 59.92% | 96.32% | 128.83% | 35.36% | 21.05% | 14.44% | Upgrade
|
| Free Cash Flow Margin | -253.13% | 75.50% | 51.48% | 62.95% | 54.06% | 31.78% | Upgrade
|
| EBITDA | 12.57 | 11.44 | 11.95 | 13.66 | 13.22 | 12.54 | Upgrade
|
| EBITDA Margin | 47.52% | 54.06% | 57.80% | 62.25% | 61.19% | 55.87% | Upgrade
|
| D&A For EBITDA | 2.69 | 1.14 | 0.9 | 0.6 | 1.06 | 1.04 | Upgrade
|
| EBIT | 9.88 | 10.3 | 11.05 | 13.06 | 12.16 | 11.5 | Upgrade
|
| EBIT Margin | 37.35% | 48.68% | 53.45% | 59.51% | 56.30% | 51.23% | Upgrade
|
| Effective Tax Rate | - | - | - | 29.85% | 32.89% | 53.78% | Upgrade
|
| Revenue as Reported | 26.46 | 21.16 | 20.68 | 21.94 | 21.61 | 22.45 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.